APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurological Biomarkers

A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention. Examples of classical biomarkers are measurable alterations in blood pressure and blood glucose in diabetes mellitus.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention. Examples of classical biomarkers are measurable alterations in blood pressure and blood glucose in diabetes mellitus.

Selected research

Market Structure

Global Neurological Biomarkers Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025194 pages

Choose your research edition.

Industry ResearchNeurological Biomarkers Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurological Biomarkers Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Neurological Biomarkers Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurological Biomarkers Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurological Biomarkers Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention. Examples of classical biomarkers are measurable alterations in blood pressure and blood glucose in diabetes mellitus.

Global Neurological Biomarkers key players include Thermo Fisher Scientific, Merck, Quest Diagnostics, Abbott, etc. Global top four manufacturers hold a share about 25%.

North America is the largest market, with a share over 55%, followed by Europe, and Asia-Pacific, both have a share over 35 percent.

Read the full market overview

In terms of product, Proteomics is the largest segment, with a share about 30%. And in terms of application, the largest application is Proteomics, followed by Drug Discovery, Personalized Medicine, etc.

This report provides an overview of the global Neurological Biomarkers market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurological Biomarkers and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurological Biomarkers sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neurological Biomarkers market size, projected growth trends, production technologies, key applications, and end-use industries.

Neurological Biomarkers Segment by Company

Thermo Fisher Scientific

Merck

Quest Diagnostics

Abbott

Roche

Illumina

Bio-Rad Laboratories

QIAGEN

Myriad RBM

Cisbio Bioassays

Athena Diagnostics

BGI

Wuxi APP

Aepodia

Proteome Sciences

Genewiz

Neurological Biomarkers Segment by Type

Proteomics

Genomics

Imaging

Bioinformatics

Others

Neurological Biomarkers Segment by Application

Diagnostics

Drug Discovery

Personalized Medicine

Others

Neurological Biomarkers Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurological Biomarkers market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurological Biomarkers and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurological Biomarkers.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neurological Biomarkers market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neurological Biomarkers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Neurological Biomarkers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Neurological Biomarkers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Neurological Biomarkers Industry Trends Table 2. Neurological Biomarkers Industry Drivers Table 3. Neurological Biomarkers Industry Opportunities and Challenges Table 4. Neurological Biomarkers Industry Restraints Table 5. Global Neurological Biomarkers Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Neurological Biomarkers Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Neurological Biomarkers Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Neurological Biomarkers Sales Market Share by Manufacturers Table 9. Global Neurological Biomarkers Average Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 10. Global Neurological Biomarkers Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Neurological Biomarkers Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Neurological Biomarkers Manufacturers, Product Type & Application Table 13. Global Neurological Biomarkers Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Neurological Biomarkers by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Proteomics Table 17. Major Manufacturers of Genomics Table 18. Major Manufacturers of Imaging Table 19. Major Manufacturers of Bioinformatics Table 20. Major Manufacturers of Others Table 21. Global Neurological Biomarkers Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Neurological Biomarkers Sales by Type (2021-2026) & (K Units) Table 23. Global Neurological Biomarkers Sales by Type (2027-2032) & (K Units) Table 24. Global Neurological Biomarkers Sales Market Share by Type (2021-2026) Table 25. Global Neurological Biomarkers Sales Market Share by Type (2027-2032) Table 26. Global Neurological Biomarkers Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Neurological Biomarkers Revenue by Type (2021-2026) & (K Units) Table 28. Global Neurological Biomarkers Revenue by Type (2027-2032) & (K Units) Table 29. Global Neurological Biomarkers Revenue Market Share by Type (2021-2026) Table 30. Global Neurological Biomarkers Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Diagnostics Table 32. Major Manufacturers of Drug Discovery Table 33. Major Manufacturers of Personalized Medicine Table 34. Major Manufacturers of Others Table 35. Global Neurological Biomarkers Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Neurological Biomarkers Sales by Application (2021-2026) & (K Units) Table 37. Global Neurological Biomarkers Sales by Application (2027-2032) & (K Units) Table 38. Global Neurological Biomarkers Sales Market Share by Application (2021-2026) Table 39. Global Neurological Biomarkers Sales Market Share by Application (2027-2032) Table 40. Global Neurological Biomarkers Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Neurological Biomarkers Revenue by Application (2021-2026) & (K Units) Table 42. Global Neurological Biomarkers Revenue by Application (2027-2032) & (K Units) Table 43. Global Neurological Biomarkers Revenue Market Share by Application (2021-2026) Table 44. Global Neurological Biomarkers Revenue Market Share by Application (2027-2032) Table 45. Global Neurological Biomarkers Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Neurological Biomarkers Sales by Region (2021-2026) & (K Units) Table 47. Global Neurological Biomarkers Sales Market Share by Region (2021-2026) Table 48. Global Neurological Biomarkers Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Neurological Biomarkers Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Neurological Biomarkers Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Neurological Biomarkers Sales by Country (2021-2026) & (K Units) Table 52. North America Neurological Biomarkers Sales by Country (2027-2032) & (K Units) Table 53. Europe Neurological Biomarkers Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Neurological Biomarkers Sales by Country (2021-2026) & (K Units) Table 55. Europe Neurological Biomarkers Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Neurological Biomarkers Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Neurological Biomarkers Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Neurological Biomarkers Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Neurological Biomarkers Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Neurological Biomarkers Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Neurological Biomarkers Sales by Country (2027-2032) & (K Units) Table 62. Global Neurological Biomarkers Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Neurological Biomarkers Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Neurological Biomarkers Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Neurological Biomarkers Revenue Market Share by Region (2021-2026) Table 66. Global Neurological Biomarkers Revenue Market Share by Region (2027-2032) Table 67. Thermo Fisher Scientific Company Information Table 68. Thermo Fisher Scientific Business Overview Table 69. Thermo Fisher Scientific Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Thermo Fisher Scientific Neurological Biomarkers Product Portfolio Table 71. Thermo Fisher Scientific Recent Development Table 72. Merck Company Information Table 73. Merck Business Overview Table 74. Merck Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Merck Neurological Biomarkers Product Portfolio Table 76. Merck Recent Development Table 77. Quest Diagnostics Company Information Table 78. Quest Diagnostics Business Overview Table 79. Quest Diagnostics Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Quest Diagnostics Neurological Biomarkers Product Portfolio Table 81. Quest Diagnostics Recent Development Table 82. Abbott Company Information Table 83. Abbott Business Overview Table 84. Abbott Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Abbott Neurological Biomarkers Product Portfolio Table 86. Abbott Recent Development Table 87. Roche Company Information Table 88. Roche Business Overview Table 89. Roche Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Roche Neurological Biomarkers Product Portfolio Table 91. Roche Recent Development Table 92. Illumina Company Information Table 93. Illumina Business Overview Table 94. Illumina Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Illumina Neurological Biomarkers Product Portfolio Table 96. Illumina Recent Development Table 97. Bio-Rad Laboratories Company Information Table 98. Bio-Rad Laboratories Business Overview Table 99. Bio-Rad Laboratories Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Bio-Rad Laboratories Neurological Biomarkers Product Portfolio Table 101. Bio-Rad Laboratories Recent Development Table 102. QIAGEN Company Information Table 103. QIAGEN Business Overview Table 104. QIAGEN Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. QIAGEN Neurological Biomarkers Product Portfolio Table 106. QIAGEN Recent Development Table 107. Myriad RBM Company Information Table 108. Myriad RBM Business Overview Table 109. Myriad RBM Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Myriad RBM Neurological Biomarkers Product Portfolio Table 111. Myriad RBM Recent Development Table 112. Cisbio Bioassays Company Information Table 113. Cisbio Bioassays Business Overview Table 114. Cisbio Bioassays Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Cisbio Bioassays Neurological Biomarkers Product Portfolio Table 116. Cisbio Bioassays Recent Development Table 117. Athena Diagnostics Company Information Table 118. Athena Diagnostics Business Overview Table 119. Athena Diagnostics Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Athena Diagnostics Neurological Biomarkers Product Portfolio Table 121. Athena Diagnostics Recent Development Table 122. BGI Company Information Table 123. BGI Business Overview Table 124. BGI Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. BGI Neurological Biomarkers Product Portfolio Table 126. BGI Recent Development Table 127. Wuxi APP Company Information Table 128. Wuxi APP Business Overview Table 129. Wuxi APP Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Wuxi APP Neurological Biomarkers Product Portfolio Table 131. Wuxi APP Recent Development Table 132. Aepodia Company Information Table 133. Aepodia Business Overview Table 134. Aepodia Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Aepodia Neurological Biomarkers Product Portfolio Table 136. Aepodia Recent Development Table 137. Proteome Sciences Company Information Table 138. Proteome Sciences Business Overview Table 139. Proteome Sciences Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Proteome Sciences Neurological Biomarkers Product Portfolio Table 141. Proteome Sciences Recent Development Table 142. Genewiz Company Information Table 143. Genewiz Business Overview Table 144. Genewiz Neurological Biomarkers Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Genewiz Neurological Biomarkers Product Portfolio Table 146. Genewiz Recent Development Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Neurological Biomarkers Distributors List Table 150. Neurological Biomarkers Customers List Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. Neurological Biomarkers Product Image Figure 2. Global Neurological Biomarkers Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurological Biomarkers Market Size (2021-2032) & (US$ Million) Figure 4. Global Neurological Biomarkers Sales (2021-2032) & (K Units) Figure 5. Global Neurological Biomarkers Average Price (USD/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Neurological Biomarkers Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Proteomics Image Figure 9. Genomics Image Figure 10. Imaging Image Figure 11. Bioinformatics Image Figure 12. Others Image Figure 13. Global Neurological Biomarkers Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Neurological Biomarkers Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Neurological Biomarkers Sales Market Share by Type (2021-2032) Figure 16. Global Neurological Biomarkers Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Neurological Biomarkers Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Neurological Biomarkers Revenue Market Share by Type (2021-2032) Figure 19. Diagnostics Image Figure 20. Drug Discovery Image Figure 21. Personalized Medicine Image Figure 22. Others Image Figure 23. Global Neurological Biomarkers Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Neurological Biomarkers Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Neurological Biomarkers Sales Market Share by Application (2021-2032) Figure 26. Global Neurological Biomarkers Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Neurological Biomarkers Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Neurological Biomarkers Revenue Market Share by Application (2021-2032) Figure 29. North America Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Neurological Biomarkers Sales Market Share by Country (2021-2032) Figure 31. U.S. Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Neurological Biomarkers Sales Market Share by Country (2021-2032) Figure 36. Germany Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Neurological Biomarkers Sales Market Share by Country (2021-2032) Figure 43. China Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Neurological Biomarkers Sales Market Share by Country (2021-2032) Figure 51. Brazil Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Neurological Biomarkers Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Neurological Biomarkers Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Neurological Biomarkers Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Neurological Biomarkers Revenue (2021-2032) & (US$ Million) Figure 62. North America Neurological Biomarkers Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Neurological Biomarkers Revenue (2021-2032) & (US$ Million) Figure 64. Europe Neurological Biomarkers Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Neurological Biomarkers Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Neurological Biomarkers Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Neurological Biomarkers Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Neurological Biomarkers Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Neurological Biomarkers Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Neurological Biomarkers Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Proteomics
  • Genomics
  • Imaging
  • Bioinformatics
  • Others
Applications
  • Diagnostics
  • Drug Discovery
  • Personalized Medicine
  • Others
Companies covered
  • Thermo Fisher Scientific
  • Merck
  • Quest Diagnostics
  • Abbott
  • Roche
  • Illumina
  • Bio-Rad Laboratories
  • QIAGEN
  • Myriad RBM
  • Cisbio Bioassays
  • Athena Diagnostics
  • BGI
  • Wuxi APP
  • Aepodia
  • Proteome Sciences
  • Genewiz

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neurological Biomarkers Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neurological Biomarkers Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Neurological Biomarkers Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Neurological Biomarkers Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Neurological Biomarkers Market Dynamics
  1. 2.1 Neurological Biomarkers Industry Trends
  2. 2.2 Neurological Biomarkers Industry Drivers
  3. 2.3 Neurological Biomarkers Industry Opportunities and Challenges
  4. 2.4 Neurological Biomarkers Industry Restraints
3 Neurological Biomarkers Market by Manufacturers
  1. 3.1 Global Neurological Biomarkers Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Neurological Biomarkers Sales by Manufacturers (2021-2026)
  3. 3.3 Global Neurological Biomarkers Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Neurological Biomarkers Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neurological Biomarkers Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Neurological Biomarkers Manufacturers, Product Type & Application
  7. 3.7 Global Neurological Biomarkers Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neurological Biomarkers Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neurological Biomarkers Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neurological Biomarkers Tier 1, Tier 2, and Tier 3
4 Neurological Biomarkers Market by Type
  1. 4.1 Neurological Biomarkers Type Introduction
  2. 4.1.1 Proteomics
  3. 4.1.2 Genomics
  4. 4.1.3 Imaging
  5. 4.1.4 Bioinformatics
  6. 4.1.5 Others
  7. 4.2 Global Neurological Biomarkers Sales by Type
  8. 4.2.1 Global Neurological Biomarkers Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Neurological Biomarkers Sales by Type (2021-2032)
  10. 4.2.3 Global Neurological Biomarkers Sales Market Share by Type (2021-2032)
  11. 4.3 Global Neurological Biomarkers Revenue by Type
  12. 4.3.1 Global Neurological Biomarkers Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Neurological Biomarkers Revenue by Type (2021-2032)
  14. 4.3.3 Global Neurological Biomarkers Revenue Market Share by Type (2021-2032)
5 Neurological Biomarkers Market by Application
  1. 5.1 Neurological Biomarkers Application Introduction
  2. 5.1.1 Diagnostics
  3. 5.1.2 Drug Discovery
  4. 5.1.3 Personalized Medicine
  5. 5.1.4 Others
  6. 5.2 Global Neurological Biomarkers Sales by Application
  7. 5.2.1 Global Neurological Biomarkers Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Neurological Biomarkers Sales by Application (2021-2032)
  9. 5.2.3 Global Neurological Biomarkers Sales Market Share by Application (2021-2032)
  10. 5.3 Global Neurological Biomarkers Revenue by Application
  11. 5.3.1 Global Neurological Biomarkers Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Neurological Biomarkers Revenue by Application (2021-2032)
  13. 5.3.3 Global Neurological Biomarkers Revenue Market Share by Application (2021-2032)
6 Global Neurological Biomarkers Sales by Region
  1. 6.1 Global Neurological Biomarkers Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurological Biomarkers Sales by Region (2021-2032)
  3. 6.2.1 Global Neurological Biomarkers Sales by Region (2021-2026)
  4. 6.2.2 Global Neurological Biomarkers Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neurological Biomarkers Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Neurological Biomarkers Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Neurological Biomarkers Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Neurological Biomarkers Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Neurological Biomarkers Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Neurological Biomarkers Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Neurological Biomarkers Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Neurological Biomarkers Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Neurological Biomarkers Revenue by Region
  1. 7.1 Global Neurological Biomarkers Revenue by Region
  2. 7.1.1 Global Neurological Biomarkers Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Neurological Biomarkers Revenue by Region (2021-2026)
  4. 7.1.3 Global Neurological Biomarkers Revenue by Region (2027-2032)
  5. 7.1.4 Global Neurological Biomarkers Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Neurological Biomarkers Revenue (2021-2032)
  8. 7.2.2 North America Neurological Biomarkers Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Neurological Biomarkers Revenue (2021-2032)
  11. 7.3.2 Europe Neurological Biomarkers Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Neurological Biomarkers Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Neurological Biomarkers Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Neurological Biomarkers Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Neurological Biomarkers Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific Neurological Biomarkers Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Neurological Biomarkers Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Quest Diagnostics
  14. 8.3.1 Quest Diagnostics Company Information
  15. 8.3.2 Quest Diagnostics Business Overview
  16. 8.3.3 Quest Diagnostics Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Quest Diagnostics Neurological Biomarkers Product Portfolio
  18. 8.3.5 Quest Diagnostics Recent Developments
  19. 8.4 Abbott
  20. 8.4.1 Abbott Company Information
  21. 8.4.2 Abbott Business Overview
  22. 8.4.3 Abbott Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Abbott Neurological Biomarkers Product Portfolio
  24. 8.4.5 Abbott Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Neurological Biomarkers Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Illumina
  32. 8.6.1 Illumina Company Information
  33. 8.6.2 Illumina Business Overview
  34. 8.6.3 Illumina Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Illumina Neurological Biomarkers Product Portfolio
  36. 8.6.5 Illumina Recent Developments
  37. 8.7 Bio-Rad Laboratories
  38. 8.7.1 Bio-Rad Laboratories Company Information
  39. 8.7.2 Bio-Rad Laboratories Business Overview
  40. 8.7.3 Bio-Rad Laboratories Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bio-Rad Laboratories Neurological Biomarkers Product Portfolio
  42. 8.7.5 Bio-Rad Laboratories Recent Developments
  43. 8.8 QIAGEN
  44. 8.8.1 QIAGEN Company Information
  45. 8.8.2 QIAGEN Business Overview
  46. 8.8.3 QIAGEN Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 QIAGEN Neurological Biomarkers Product Portfolio
  48. 8.8.5 QIAGEN Recent Developments
  49. 8.9 Myriad RBM
  50. 8.9.1 Myriad RBM Company Information
  51. 8.9.2 Myriad RBM Business Overview
  52. 8.9.3 Myriad RBM Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Myriad RBM Neurological Biomarkers Product Portfolio
  54. 8.9.5 Myriad RBM Recent Developments
  55. 8.10 Cisbio Bioassays
  56. 8.10.1 Cisbio Bioassays Company Information
  57. 8.10.2 Cisbio Bioassays Business Overview
  58. 8.10.3 Cisbio Bioassays Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Cisbio Bioassays Neurological Biomarkers Product Portfolio
  60. 8.10.5 Cisbio Bioassays Recent Developments
  61. 8.11 Athena Diagnostics
  62. 8.11.1 Athena Diagnostics Company Information
  63. 8.11.2 Athena Diagnostics Business Overview
  64. 8.11.3 Athena Diagnostics Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Athena Diagnostics Neurological Biomarkers Product Portfolio
  66. 8.11.5 Athena Diagnostics Recent Developments
  67. 8.12 BGI
  68. 8.12.1 BGI Company Information
  69. 8.12.2 BGI Business Overview
  70. 8.12.3 BGI Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BGI Neurological Biomarkers Product Portfolio
  72. 8.12.5 BGI Recent Developments
  73. 8.13 Wuxi APP
  74. 8.13.1 Wuxi APP Company Information
  75. 8.13.2 Wuxi APP Business Overview
  76. 8.13.3 Wuxi APP Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Wuxi APP Neurological Biomarkers Product Portfolio
  78. 8.13.5 Wuxi APP Recent Developments
  79. 8.14 Aepodia
  80. 8.14.1 Aepodia Company Information
  81. 8.14.2 Aepodia Business Overview
  82. 8.14.3 Aepodia Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Aepodia Neurological Biomarkers Product Portfolio
  84. 8.14.5 Aepodia Recent Developments
  85. 8.15 Proteome Sciences
  86. 8.15.1 Proteome Sciences Company Information
  87. 8.15.2 Proteome Sciences Business Overview
  88. 8.15.3 Proteome Sciences Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Proteome Sciences Neurological Biomarkers Product Portfolio
  90. 8.15.5 Proteome Sciences Recent Developments
  91. 8.16 Genewiz
  92. 8.16.1 Genewiz Company Information
  93. 8.16.2 Genewiz Business Overview
  94. 8.16.3 Genewiz Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Genewiz Neurological Biomarkers Product Portfolio
  96. 8.16.5 Genewiz Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neurological Biomarkers Value Chain Analysis
  2. 9.1.1 Neurological Biomarkers Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neurological Biomarkers Production Mode & Process
  6. 9.2 Neurological Biomarkers Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neurological Biomarkers Distributors
  9. 9.2.3 Neurological Biomarkers Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst